Kenneth Moch

President, Euclidean Life Science Advisors, LLC and Serial Biotech Entrepreneur

Ken has broad expertise building, financing and leading life science companies, having co-founded or served as President & CEO of six life sciences companies. Through these and numerous Board involvements, Ken has worked to develop new medicines against life threatening conditions including Alzheimer’s and other neurodegenerative diseases, viral diseases, cardiovascular disease, diabetes, and cancer. Early in his career Ken pioneered the use of cord blood stem cells in transplantation therapy and launched the first cord blood storage bank. Ken started his career in biotech drug development as a co-founder and Vice President of The Liposome Company, which pioneered the use of lipid nanoparticles. He has also been a Managing Director of Healthcare Investment Banking at ThinkEquity Partners and a management consultant with McKinsey & Company, Inc. Ken served for two decades on the Governing Board of the Biotechnology Innovation Organization, most recently focusing on bioethical issues as well as on the difficulties of developing new medicines for highly prevalent chronic diseases, and was the Chairman of BioNJ, helping to build the biotech infrastructure within New Jersey. He is a founding member of the Working Group on Compassionate Use and Pre-Approval Access at NYU, where he is also a Faculty Affiliate in the Department of Medical Ethics. His involvement in medical ethics was catalyzed by experiences documented in a Harvard Business School case study, “Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix.” Ken holds an A.B. in biochemistry with a minor in health policy from Princeton University and an MBA from Stanford University.